RhumbLine Advisers’s Aardvark Therapeutics AARD Stock Holding History

RhumbLine Advisers’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,679	Closed	-$25.2K	–	4280
2026 Q1	$25.2K	Sell	6,679 -875	-12%	-$9.07K	﹤0.01%	3694
2025 Q4	$99.1K	Buy	7,554 +1,849	+32%	+$23.1K	﹤0.01%	3478
2025 Q3	$75.8K	Buy	5,705 +216	+4%	+$2.44K	﹤0.01%	3590
2025 Q2	$74.2K	Buy	+5,489	New	+$56.6K	﹤0.01%	3606

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

RhumbLine Advisers's AARD Position: Q2 2026 in Review

RhumbLine Advisers sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 6,679 shares — an estimated $25.2K sold.

RhumbLine Advisers first reported a position in AARD in Q2 2025 and held it in 4 quarters. The position peaked at $99.1K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

RhumbLine Advisers reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
RhumbLine Advisers sold 6,679 Aardvark Therapeutics shares in Q2 2026, an estimated $25.2K.
RhumbLine Advisers first reported a position in Aardvark Therapeutics in Q2 2025 and held it in 4 quarters.
RhumbLine Advisers's Aardvark Therapeutics position peaked at $99.1K in Q4 2025.
71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.